Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation | ||
By: PR Newswire Association LLC. - 24 Apr 2019 | Back to overview list |
|
SEATTLE and VANCOUVER, British Columbia, April 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the last study visit for the last subject enrolled in the ORCA-1 trial occurred on April 23, 2019. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter. ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other addiction indications. ORCA-1 was initiated in October 2018 and enrolled 254 smokers at eight centers across the United States. Importantly, the trial's Data Safety Monitoring Committee met recently to conduct its final safety review and concluded there are no safety concerns for subjects or study conduct issues, and the trial should continue for completion. Dr. Cindy Jacobs, Chief Medical Officer at Achieve commented, "Completing this trial represents a significant milestone in the cytisinicline development program and we continue to be impressed by the efficient conduct of our investigators and the commitment of the subjects who, like millions of people, are combatting nicotine addiction." Additional information on cytisinicline and the ORCA program can be found at www.achievelifesciences.com and www.orcaprogram.com. About Cytisinicline Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking. As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction. About ORCA-1 Forward Looking Statements Achieve Contact "ORCA is a trademark of Achieve Life Sciences, Inc." 1World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017 View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-announces-last-subject-last-visit-completed-in-phase-2b-orca-1-trial-of-cytisinicline-for-smoking-cessation-300837024.html SOURCE Achieve Life Sciences, Inc. |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |